APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gaucher Disease (GD) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gaucher Disease (GD) Drugs Market Outlook and Growth Opportunities 2026

19 December 2025196 pages

Choose your research edition.

Industry ResearchGaucher Disease (GD) Drugs Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Gaucher Disease (GD) Drugs Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Gaucher Disease (GD) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gaucher Disease (GD) Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Gaucher Disease (GD) Drugs Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Gaucher Disease (GD) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gaucher Disease (GD) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gaucher Disease (GD) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gaucher Disease (GD) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gaucher Disease (GD) Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gaucher Disease (GD) Drugs market include Sanofi, Pfizer (Protalix), Shire, ISU ABXIS and Actelion Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Gaucher Disease (GD) Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gaucher Disease (GD) Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gaucher Disease (GD) Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Gaucher Disease (GD) Drugs market.

Gaucher Disease (GD) Drugs Segment by Company

Sanofi

Pfizer (Protalix)

Shire

ISU ABXIS

Actelion Pharma

Gaucher Disease (GD) Drugs Segment by Type

Enzyme Replacement Therapy

Substrate Reduction Therapy

Gaucher Disease (GD) Drugs Segment by Application

Non-neuronopathic Gaucher Disease

Neuronopathic Gaucher Disease

Gaucher Disease (GD) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Gaucher Disease (GD) Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Gaucher Disease (GD) Drugs key companies, revenue, market share, and recent developments.

3. To split the Gaucher Disease (GD) Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Gaucher Disease (GD) Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gaucher Disease (GD) Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Gaucher Disease (GD) Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gaucher Disease (GD) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gaucher Disease (GD) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gaucher Disease (GD) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gaucher Disease (GD) Drugs industry.

Chapter 3: Detailed analysis of Gaucher Disease (GD) Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Gaucher Disease (GD) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Gaucher Disease (GD) Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gaucher Disease (GD) Drugs Industry Trends Table 2. Gaucher Disease (GD) Drugs Industry Drivers Table 3. Gaucher Disease (GD) Drugs Industry Opportunities and Challenges Table 4. Gaucher Disease (GD) Drugs Industry Restraints Table 5. Global Gaucher Disease (GD) Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gaucher Disease (GD) Drugs Revenue Share by Company (2021-2026) Table 7. Global Gaucher Disease (GD) Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Gaucher Disease (GD) Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Gaucher Disease (GD) Drugs Company, Product Type & Application Table 10. Global Gaucher Disease (GD) Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Gaucher Disease (GD) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Enzyme Replacement Therapy Table 15. Significant Companies of Substrate Reduction Therapy Table 16. Global Gaucher Disease (GD) Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Gaucher Disease (GD) Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Gaucher Disease (GD) Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Gaucher Disease (GD) Drugs Sales Value Share by Type (2021-2026) Table 20. Global Gaucher Disease (GD) Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Non-neuronopathic Gaucher Disease Table 22. Significant Companies of Neuronopathic Gaucher Disease Table 23. Global Gaucher Disease (GD) Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Gaucher Disease (GD) Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Gaucher Disease (GD) Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Gaucher Disease (GD) Drugs Sales Value Share by Application (2021-2026) Table 27. Global Gaucher Disease (GD) Drugs Sales Value Share by Application (2027-2032) Table 28. Global Gaucher Disease (GD) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Gaucher Disease (GD) Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Gaucher Disease (GD) Drugs Sales Value Share by Region (2021-2026) Table 31. Global Gaucher Disease (GD) Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Gaucher Disease (GD) Drugs Sales Value Share by Region (2027-2032) Table 33. Global Gaucher Disease (GD) Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Gaucher Disease (GD) Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Gaucher Disease (GD) Drugs Sales Value Market Share by Country (2021-2026) Table 36. Global Gaucher Disease (GD) Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Gaucher Disease (GD) Drugs Sales Value Market Share by Country (2027-2032) Table 38. Sanofi Company Information Table 39. Sanofi Business Overview Table 40. Sanofi Gaucher Disease (GD) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Sanofi Gaucher Disease (GD) Drugs Product Portfolio Table 42. Sanofi Recent Development Table 43. Pfizer (Protalix) Company Information Table 44. Pfizer (Protalix) Business Overview Table 45. Pfizer (Protalix) Gaucher Disease (GD) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Pfizer (Protalix) Gaucher Disease (GD) Drugs Product Portfolio Table 47. Pfizer (Protalix) Recent Development Table 48. Shire Company Information Table 49. Shire Business Overview Table 50. Shire Gaucher Disease (GD) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Shire Gaucher Disease (GD) Drugs Product Portfolio Table 52. Shire Recent Development Table 53. ISU ABXIS Company Information Table 54. ISU ABXIS Business Overview Table 55. ISU ABXIS Gaucher Disease (GD) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. ISU ABXIS Gaucher Disease (GD) Drugs Product Portfolio Table 57. ISU ABXIS Recent Development Table 58. Actelion Pharma Company Information Table 59. Actelion Pharma Business Overview Table 60. Actelion Pharma Gaucher Disease (GD) Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Actelion Pharma Gaucher Disease (GD) Drugs Product Portfolio Table 62. Actelion Pharma Recent Development Table 63. Research Programs/Design for This Report Table 64. Authors List of This Report Table 65. Secondary Sources Table 66. Primary Sources List of Figures Figure 1. Gaucher Disease (GD) Drugs Product Image Figure 2. Global Gaucher Disease (GD) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gaucher Disease (GD) Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Gaucher Disease (GD) Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Enzyme Replacement Therapy Image Figure 8. Substrate Reduction Therapy Image Figure 9. Global Gaucher Disease (GD) Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Gaucher Disease (GD) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Gaucher Disease (GD) Drugs Sales Value Share by Type (2021-2032) Figure 12. Non-neuronopathic Gaucher Disease Image Figure 13. Neuronopathic Gaucher Disease Image Figure 14. Global Gaucher Disease (GD) Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Gaucher Disease (GD) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Gaucher Disease (GD) Drugs Sales Value Share by Application (2021-2032) Figure 17. Global Gaucher Disease (GD) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Gaucher Disease (GD) Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Gaucher Disease (GD) Drugs Sales Value (2021-2032) & (US$ Million) Figure 20. North America Gaucher Disease (GD) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Gaucher Disease (GD) Drugs Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Gaucher Disease (GD) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Gaucher Disease (GD) Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Gaucher Disease (GD) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Gaucher Disease (GD) Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. South America Gaucher Disease (GD) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Gaucher Disease (GD) Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Gaucher Disease (GD) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Enzyme Replacement Therapy
  • Substrate Reduction Therapy
Applications
  • Non-neuronopathic Gaucher Disease
  • Neuronopathic Gaucher Disease
Companies covered
  • Sanofi
  • Pfizer (Protalix)
  • Shire
  • ISU ABXIS
  • Actelion Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Gaucher Disease (GD) Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Gaucher Disease (GD) Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Gaucher Disease (GD) Drugs Market Dynamics
  1. 2.1 Gaucher Disease (GD) Drugs Industry Trends
  2. 2.2 Gaucher Disease (GD) Drugs Industry Drivers
  3. 2.3 Gaucher Disease (GD) Drugs Industry Opportunities and Challenges
  4. 2.4 Gaucher Disease (GD) Drugs Industry Restraints
3 Gaucher Disease (GD) Drugs Market by Company
  1. 3.1 Global Gaucher Disease (GD) Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Gaucher Disease (GD) Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Gaucher Disease (GD) Drugs Company Ranking (2024-2026)
  4. 3.4 Global Gaucher Disease (GD) Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Gaucher Disease (GD) Drugs Company Product Type and Application
  6. 3.6 Global Gaucher Disease (GD) Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Gaucher Disease (GD) Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Gaucher Disease (GD) Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Gaucher Disease (GD) Drugs Market by Type
  1. 4.1 Gaucher Disease (GD) Drugs Type Introduction
  2. 4.1.1 Enzyme Replacement Therapy
  3. 4.1.2 Substrate Reduction Therapy
  4. 4.2 Global Gaucher Disease (GD) Drugs Sales Value by Type
  5. 4.2.1 Global Gaucher Disease (GD) Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Gaucher Disease (GD) Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Gaucher Disease (GD) Drugs Sales Value Share by Type (2021-2032)
5 Gaucher Disease (GD) Drugs Market by Application
  1. 5.1 Gaucher Disease (GD) Drugs Application Introduction
  2. 5.1.1 Non-neuronopathic Gaucher Disease
  3. 5.1.2 Neuronopathic Gaucher Disease
  4. 5.2 Global Gaucher Disease (GD) Drugs Sales Value by Application
  5. 5.2.1 Global Gaucher Disease (GD) Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Gaucher Disease (GD) Drugs Sales Value by Application (2021-2032)
  7. 5.2.3 Global Gaucher Disease (GD) Drugs Sales Value Share by Application (2021-2032)
6 Gaucher Disease (GD) Drugs Regional Value Analysis
  1. 6.1 Global Gaucher Disease (GD) Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gaucher Disease (GD) Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Gaucher Disease (GD) Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Gaucher Disease (GD) Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Gaucher Disease (GD) Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Gaucher Disease (GD) Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Gaucher Disease (GD) Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Gaucher Disease (GD) Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Gaucher Disease (GD) Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Gaucher Disease (GD) Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Gaucher Disease (GD) Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Gaucher Disease (GD) Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Gaucher Disease (GD) Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Gaucher Disease (GD) Drugs Sales Value Share by Country, 2025 VS 2032
7 Gaucher Disease (GD) Drugs Country-level Value Analysis
  1. 7.1 Global Gaucher Disease (GD) Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gaucher Disease (GD) Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Gaucher Disease (GD) Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Gaucher Disease (GD) Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Gaucher Disease (GD) Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Gaucher Disease (GD) Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Gaucher Disease (GD) Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Gaucher Disease (GD) Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Gaucher Disease (GD) Drugs Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Pfizer (Protalix)
  8. 8.2.1 Pfizer (Protalix) Company Information
  9. 8.2.2 Pfizer (Protalix) Business Overview
  10. 8.2.3 Pfizer (Protalix) Gaucher Disease (GD) Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer (Protalix) Gaucher Disease (GD) Drugs Product Portfolio
  12. 8.2.5 Pfizer (Protalix) Recent Developments
  13. 8.3 Shire
  14. 8.3.1 Shire Company Information
  15. 8.3.2 Shire Business Overview
  16. 8.3.3 Shire Gaucher Disease (GD) Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shire Gaucher Disease (GD) Drugs Product Portfolio
  18. 8.3.5 Shire Recent Developments
  19. 8.4 ISU ABXIS
  20. 8.4.1 ISU ABXIS Company Information
  21. 8.4.2 ISU ABXIS Business Overview
  22. 8.4.3 ISU ABXIS Gaucher Disease (GD) Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 ISU ABXIS Gaucher Disease (GD) Drugs Product Portfolio
  24. 8.4.5 ISU ABXIS Recent Developments
  25. 8.5 Actelion Pharma
  26. 8.5.1 Actelion Pharma Company Information
  27. 8.5.2 Actelion Pharma Business Overview
  28. 8.5.3 Actelion Pharma Gaucher Disease (GD) Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Actelion Pharma Gaucher Disease (GD) Drugs Product Portfolio
  30. 8.5.5 Actelion Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst